{"article_title": "Sandoz Files Application For Biosimilar To Amgen's Enbrel", "article_keywords": ["files", "biosimilar", "enbrel", "usedto", "amgens", "drug", "amgen", "application", "incs", "uses", "york", "sandoz", "view"], "article_url": "http://www.law360.com/articles/710287/sandoz-files-application-for-biosimilar-to-amgen-s-enbrel", "article_text": "Sandoz Files Application For Biosimilar To Amgen's Enbrel\n\nLaw360, New York (October 2, 2015, 4:48 PM ET) -- The U.S. Food and Drug Administration has accepted Sandoz Inc.'s application for a proposed biosimilar to Amgen Inc.'s biologic arthritis drug Enbrel, the company announced on Friday, about a month after it launched its first biosimilar to an Amgen drug.\n\n\n\nThe Novartis AG subsidiary is seeking approval of the biosimilar for all uses included on Enbrel's label. The biosimilar is a tumor necrosis factor alpha inhibitor, also known as an anti-TNF \u2014 a drug that suppresses the body's response to cell death \u2014 and is used...\n\nTo view the full article, register now.", "article_metadata": {"description": "The U.S. Food and Drug Administration has accepted Sandoz Inc.&#39;s application for a proposed biosimilar to Amgen Inc.&#39;s biologic arthritis drug Enbrel, the company announced on Friday, about a month after it launched its first biosimilar to an Amgen drug.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/710287/sandoz-files-application-for-biosimilar-to-amgen-s-enbrel", "csrf-token": "2ZyIgnHyO/NUPHpLLzd0GB5ntbLPuEc1dXbE5tlGZZfOf31v5+GZcWPFp7N6W94ZLE7n0tDafNoXoVME9PpqCQ==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/710287/sandoz-files-application-for-biosimilar-to-amgen-s-enbrel", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "Sandoz Files Application For Biosimilar To Amgen's Enbrel - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fd760e\"", "article_summary": "Sandoz Files Application For Biosimilar To Amgen's EnbrelLaw360, New York (October 2, 2015, 4:48 PM ET) -- The U.S. Food and Drug Administration has accepted Sandoz Inc.'s application for a proposed biosimilar to Amgen Inc.'s biologic arthritis drug Enbrel, the company announced on Friday, about a month after it launched its first biosimilar to an Amgen drug.\nThe Novartis AG subsidiary is seeking approval of the biosimilar for all uses included on Enbrel's label.\nThe biosimilar is a tumor necrosis factor alpha inhibitor, also known as an anti-TNF \u2014 a drug that suppresses the body's response to cell death \u2014 and is used...To view the full article, register now."}